Idera Pharma Reports Fourth Quarter And Year End 2016 Financial Results And Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the fourth quarter and year ended December 31, 2016.

During 2016, the Company:

- Completed enrollment in the dose escalation cohorts of the ipilimumab combination arm of the ongoing Phase 1/2 clinical trial of intratumoral IMO-2125 in PD-1 refractory metastatic melanoma;
- No dose-limiting toxicity reported in studied dose levels; MTD not reached;
- Patients with confirmed clinical responses have been on study past one year; and

Back to news